tradingkey.logo

LivaNova Announces 12-Month Data From Osprey Clinical Study For Moderate To Severe Obstructive Sleep Apnea, Demonstrating Strong Response And Durability Of Therapy

ReutersMay 7, 2025 9:50 AM

- LivaNova PLC LIVN.O:

  • LIVANOVA ANNOUNCES 12-MONTH DATA FROM OSPREY CLINICAL STUDY FOR MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA, DEMONSTRATING STRONG RESPONSE AND DURABILITY OF THERAPY

  • LIVANOVA : OVERALL RESPONDER RATE OF 65% , OVERALL REDUCTION IN MEDIAN APNEA-HYPOPNEA INDEX OF 68%

  • LIVANOVA : OVERALL REDUCTION IN MEDIAN OXYGEN DESATURATION INDEX OF 68%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI